ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2a and 5-HT2c receptor agonist

被引：4

作者：

Acuña-Castillo, C

Scorza, C

Reyes-Parada, M

Cassels, BK

Huidobro-Toro, JP

机构：

[1] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Fisiol,Ctr Regulac Celular & Patol, Inst Milenio Biol Fundamental & Aplicada, Santiago 1, Chile

[2] Inst Invest Biol Clemente Estable, Div Biol Celular, Montevideo, Uruguay

[3] Univ Santiago Chile, Fac Ciencias Med, Santiago, Chile

[4] Univ Chile, Fac Ciencias, Dept Quim, Inst Milenio Estudios Avanzados Biol Celular & Bi, Santiago, Chile

来源：

LIFE SCIENCES | 2000年 / 67卷 / 26期

关键词：

ALEPH-2; 5-hydroxytryptamine; 5-HT2A and 5-HT2C receptors; phenylisopropylamine derivatives;

D O I：

10.1016/S0024-3205(00)00906-1

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

To assess the pharmacodynamic profile of ALEPH-2, a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties,Xenopus laevis oocytes were microinjected with either of the rat cRNA for the 5-HT2A or the 5-HT2C receptor. Concentration-response curves were obtained following the exposure of the oocytes to varying concentrations of either ALEPH-2 or 5-hydroxy-tryptamine (5-HT) for 10 s. ALEPH-2 is a partial agonist on the 5-HT,,receptor with a similar potency to 5-HT. In contrast, ALEPH-2 is a full 5-HT2C receptor agonist and is about 15-fold less potent than 5-HT. Pre-application of 1 muM ritanserin antagonized the responses induced by 5-HT and ALEPH-2 to the same extent; however, the 5-HT2A receptor is more sensitive to ritanserin blockade than the 5-HT2C receptor. (C) 2000 Elsevier Science Inc. All rights reserved.

引用

页码：3241 / 3247

页数：7

共 50 条

[21] Behavioral evidence for μ-opioid and 5-HT2A receptor interactions [J].

Marek, GJ .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 474 (01) :77-83

[22] Further pharmacological characterization of 5-HT2C receptor agonist-induced inhibition of 5-HT neuronal activity in the dorsal raphe nucleus in vivo [J].

Queree, P. ;

Peters, S. ;

Sharp, T. .

BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (06) :1477-1485

[23] The 5-HT2C/2B receptor agonist, m-chlorophenylpiperazine, increases plasma glucagon levels in rats [J].

Yamada, J ;

Sugimoto, Y .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 406 (01) :153-157

[24] Therapeutic Potential of 5-HT2C Receptor Antagonists in the Treatment of Anxiety Disorders [J].

Wood, Martyn D. .

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2003, 2 (06) :383-387

[25] Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist [J].

Kimura, Y ;

Hatanaka, K ;

Naitou, Y ;

Maeno, K ;

Shimada, I ;

Koakutsu, A ;

Wanibuchi, F ;

Yamaguchi, T .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 483 (01) :37-43

[26] 5-HT7 Receptor Restrains 5-HT-induced 5-HT2A Mediated Contraction in the Isolated Abdominal Vena Cava [J].

Gonzalez-Pons, Romina ;

McRae, Kiera ;

Thompson, Janice M. ;

Watts, Stephanie W. .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 78 (02) :319-327

[27] Serotonin and drug reward:: focus on 5-HT2C receptors [J].

Higgins, GA ;

Fletcher, PJ .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 480 (1-3) :151-162

[28] Mesenteric vasoconstrictor response to 5-hydroxytryptamine in the in situ blood autoperfused rat mesentery:: involvement of 5-HT2B and/or 5-HT2C receptor activation [J].

Fernández, MD ;

Morán, A ;

Martín, ML ;

San Román, L .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 401 (02) :221-227

[29] Serotonin (5-HT) and 5-HT2A receptor agonists suppress lipolysis in primary rat adipose cells [J].

Hansson, Bjorn ;

Medina, Anya ;

Fryklund, Claes ;

Fex, Malin ;

Stenkula, Karin G. .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 474 (02) :357-363

[30] REPEATED COCAINE MODIFIES THE NEUROENDOCRINE RESPONSES TO THE 5-HT(1C) 5-HT(2)-RECEPTOR AGONIST DOI [J].

LEVY, AD ;

LI, Q ;

SANZ, MCA ;

RITTENHOUSE, PA ;

BROWNFIELD, MS ;

VANDEKAR, LD .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 221 (01) :121-127

← 1 2 3 4 5 →